S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Med-Tech Stock Set To Rally! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Med-Tech Stock Set To Rally! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Med-Tech Stock Set To Rally! (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Donald Trump says he will be in courtroom for New York trial scrutinizing his business practices
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Med-Tech Stock Set To Rally! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Med-Tech Stock Set To Rally! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Med-Tech Stock Set To Rally! (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Donald Trump says he will be in courtroom for New York trial scrutinizing his business practices
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Med-Tech Stock Set To Rally! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Med-Tech Stock Set To Rally! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Med-Tech Stock Set To Rally! (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Donald Trump says he will be in courtroom for New York trial scrutinizing his business practices
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Med-Tech Stock Set To Rally! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
Med-Tech Stock Set To Rally! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Med-Tech Stock Set To Rally! (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Donald Trump says he will be in courtroom for New York trial scrutinizing his business practices
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Forecast, Price & News

$6.74
+0.08 (+1.20%)
(As of 09/29/2023 ET)
Compare
Today's Range
$6.28
$6.74
50-Day Range
$6.06
$7.30
52-Week Range
$2.11
$13.17
Volume
4,050 shs
Average Volume
9,550 shs
Market Capitalization
$29.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
85.5% Upside
$12.50 Price Target
Short Interest
Healthy
1.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.45mentions of Corbus Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.52) to ($10.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

279th out of 970 stocks

Pharmaceutical Preparations Industry

111th out of 445 stocks


CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Price History

CRBP Stock News Headlines

Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by StockNews.com
New Breakthrough "Living Software" Has Been…
New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>
CRBP - Corbus Pharmaceuticals Holdings, Inc.
A Bio-Tech Stock That Has Been Growing Like Crazy!
Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn More
Corbus Pharmaceuticals (NASDAQ: CRBP)
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
33
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+85.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$7.91 per share

Miscellaneous

Free Float
4,123,000
Market Cap
$29.79 million
Optionable
Optionable
Beta
2.29

Social Links

10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 48)
    CEO & Director
    Comp: $890.67k
  • Mr. Sean F. Moran CPA (Age 65)
    M.B.A., CPA, MBA, Chief Financial Officer
    Comp: $579.05k
  • Dr. Rachael Brake Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $552.22k
  • Ted Jenkins
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith
    Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of HR













CRBP Stock - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price forecast for 2023?

2 equities research analysts have issued 12 month price targets for Corbus Pharmaceuticals' shares. Their CRBP share price forecasts range from $3.00 to $22.00. On average, they expect the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 85.5% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of 2023. Since then, CRBP stock has increased by 5,999.5% and is now trading at $6.74.
View the best growth stocks for 2023 here
.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 65,400 shares, a decline of 13.3% from the August 31st total of 75,400 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is currently 5.4 days. Currently, 1.5% of the shares of the stock are short sold.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($2.05) earnings per share for the quarter, beating the consensus estimate of ($3.10) by $1.05.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $6.74.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $29.79 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($11.0021) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -